The potential for long-term disease control with adebrelimab-based therapy even in biomarker-unselected populations is highlighted even in biomarker-unselected populations and the importance of combined modality strategies are highlighted.
Abstract
The integration of immune checkpoint inhibitors into first-line treatment has markedly improved outcomes for extensive-stage small cell lung cancer (ES-SCLC). Adebrelimab, a PD-L1 inhibitor, demonstrated superior overall survival in the phase 3 CAPSTONE-1 trial. We present a detailed case of a 62-year-old male with ES-SCLC who achieved a progression-free survival (PFS) of 33 months following a multimodal regimen of adebrelimab plus chemotherapy, consolidative thoracic radiotherapy, and maintenance immunotherapy. Despite low PD-L1 expression (TPS<1%), the patient exhibited profound and durable tumor regression, with the primary mass shrinking from 146×158×217 mm to 51×21 mm. Treatment was well-tolerated with only grade 1–2 adverse events. This report underscores the potential for long-term disease control with adebrelimab-based therapy even in biomarker-unselected populations and highlights the importance of combined modality strategies.
Background Small cell lung cancer (SCLC) is highly aggressive, and durable disease control after multiple treatment lines is uncommon. Anti-angiogenic therapy combined with PD-1 blockade may provide complementary antitumor effects through vascular and immune microenvironment remodeling. Case presentation We report a 64...
Ru-Zhu Wang, Yi-Shan Lu, Tian-Shu Yang et al.· Frontiers in Oncology· 1 citation
Immune checkpoint inhibitors (ICIs) have improved outcomes in selected patients with metastatic triple-negative breast cancer (mTNBC), particularly those with high programed death-ligand 1 (PD-L1) expression. However, optimal dosing strategies balancing efficacy, toxicity, and cost remain unclear. We report the case of...
Po Lin Ooi, Jamin Munchar Elias, Francis Yew Fu Tieng· Frontiers in Oncology· 0 citations
This real-world analysis shows poor outcomes in patients with progressing ES-SCLC, reflected by both short median PFS and duration of second-line treatment, along with high rates of treatment discontinuation due to progression, highlighting the urgent need for more effective and tolerable treatment options.
Daniel Moser, A. Lang-Stöberl, H. Fabikan et al.· Lung Cancer· 0 citations
SMARCA4-deficient non-small cell lung cancer (SD-NSCLC) is a highly aggressive molecular subtype. This malignancy is often diagnosed at an advanced stage, carrying a dismal prognosis and also demonstrating poor responsiveness to traditional treatment. Beyond its primary site, the disease can exhibit unusual metastatic...
T. Bu, Nan Zhang, T. Jin et al.· Frontiers in Oncology· 0 citations
These findings support multidisciplinary care as the cornerstone of long-term survival in liver cancer as an integral component of immunomodulation, DC-CIK cell therapy remodels the tumor microenvironment to facilitate other treatments, making it a defining therapeutic decision for patients with advanced liver cancer.
Shan-Shan Chen, Yun-Qing Xie, Shao-Hua Xu et al.· Frontiers in Immunology· 0 citations
Background Brain metastasis from gastric cancer carries a dismal prognosis, with median overall survival of only 3–6 months. Patients who progress on immune checkpoint inhibitor (ICI)-containing regimens have limited salvage options. HER2-low expression (IHC 1+ or IHC 2+/FISH-negative), historically excluded from anti-...
Xiao Liu, B. Ma, Meng-Jiao Yang et al.· Frontiers in Immunology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
